Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.
2.

Treatment of DVT: how long is enough and how do you predict recurrence.

Agnelli G, Becattini C.

J Thromb Thrombolysis. 2008 Feb;25(1):37-44. Review.

PMID:
17906973
3.

The role of ximelagatran in the treatment of venous thromboembolism.

Schulman S.

Pathophysiol Haemost Thromb. 2005;34 Suppl 1:18-24. Review.

PMID:
15812200
4.

Treatment options for venous thromboembolism: lessons learnt from clinical trials.

McRae S.

Thromb J. 2014 Dec 8;12(1):27. doi: 10.1186/s12959-014-0027-8.

5.

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.

Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, Mayzell G, Spyropoulos AC.

Clin Ther. 2004 Jul;26(7):1149-59.

PMID:
15336480
6.

Current management of acute symptomatic deep vein thrombosis.

Heit JA.

Am J Cardiovasc Drugs. 2001;1(1):45-50. Review.

PMID:
14728051
7.

Treatment of venous thromboembolism in cancer patients.

Lee AY.

Thromb Res. 2001 Jun 15;102(6):V195-208. Review.

PMID:
11516453
8.
9.

Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.

Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS.

Arch Intern Med. 2000 Dec 11-25;160(22):3431-6.

PMID:
11112236
10.

[Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].

Couturaud F, Pernod G, Pison C, Mismetti P, Sanchez O, Meyer G, Parent F, Girard P, Simonneau G, Drouet L, Gueret P, Jego P, Delaval P, Duhamel E, Gruel Y, Delahousse B, Regina S, Pottier P, Connaud J, Lecomte F, Provost K, Vilmans N, Gosset X, Bura-Rivière A, Meach G, Lacut K, Bosson JL, Guillot K, Mottier D, Leroyer C.

Rev Mal Respir. 2008 Sep;25(7):885-93. French.

PMID:
18946418
11.

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A.

Haematologica. 2007 Feb;92(2):199-205.

12.

Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.

Nishioka J, Goodin S.

J Oncol Pharm Pract. 2007 Jun;13(2):85-97. Review.

PMID:
17873108
13.

Emerging options in the treatment of venous thromboembolism.

Nutescu EA.

Am J Health Syst Pharm. 2004 Dec 1;61(23 Suppl 7):S12-7. Review.

PMID:
15597574
14.

Management of venous thromboembolism in the elderly.

Spyropoulos AC, Merli G.

Drugs Aging. 2006;23(8):651-71. Review.

PMID:
16964988
15.

[New treatments for venous thromboembolic disease].

Combe S, Büller HR.

J Mal Vasc. 2011 Dec;36 Suppl 1:S16-9. doi: 10.1016/S0398-0499(11)70003-8. French.

PMID:
22177764
16.

[Treatment of venous thrombosis in cancer patients: practical aspects].

Laza-Achille M, Desruennes E, Di Palma M.

Bull Cancer. 2006 Mar 1;93(3):271-81. Review. French.

17.

Oral anticoagulant therapy in venous thromboembolism.

Cosmi B, Palareti G.

Semin Vasc Med. 2003 Aug;3(3):303-14. Review.

PMID:
15199464
18.

Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?

Hull RD, Pineo GF.

Semin Thromb Hemost. 2004 Feb;30 Suppl 1:11-23. Review.

PMID:
15085462
19.

Venous thromboembolism in lymphoma: how effectively are we treating patients?

Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Daw HA.

Am J Clin Oncol. 2009 Oct;32(5):521-3. doi: 10.1097/COC.0b013e318194f72a.

PMID:
19546801
20.

Prevention and treatment of venous thromboembolism.

Pineo GF, Hull RD.

Drugs. 1996 Jul;52(1):71-92. Review.

PMID:
8799686
Items per page

Supplemental Content

Support Center